KAINOS Laboratories (TSE:4556) ROCE %: 5.62% (As of Mar. 2026)

What is KAINOS Laboratories ROCE %?

KAINOS Laboratories TSE:4556 39 ROCE % is 5.62% as of Mar. 2026. GuruFocus rates TSE:4556 with a GF Score™ of 39/100 and a GF Value™ of 円1,281.99 (Significantly Overvalued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. KAINOS Laboratories's annualized ROCE % for the quarter that ended in Mar. 2026 was 5.62%.

KAINOS Laboratories (TSE:4556) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

KAINOS Laboratories ROCE % Related Terms

KAINOS Laboratories ROCE % Historical Data

* Premium members only.

The historical data trend for KAINOS Laboratories's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

KAINOS Laboratories ROCE % Chart

KAINOS Laboratories Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

ROCE %

Get a 7-Day Free Trial

14.27

14.22

14.63

11.96

8.58

KAINOS Laboratories Semi-Annual Data
	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24	Mar25	Sep25	Mar26
ROCE %	Get a 7-Day Free Trial															12.42	14.11	9.98	11.72	5.62

39GF Score

KAINOS Laboratories Inc TSE:4556

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

KAINOS Laboratories ROCE % Calculation

KAINOS Laboratories's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2026 )		(A: Mar. 2025 )		(A: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2026 )		(A: Mar. 2025 )		(A: Mar. 2026 )
	=	640.43	/	( ( (8785.144 - 1456.639)	+	(9566.85 - 1963.36) )	/ 2 )
	=	640.43	/	( (7328.505	+	7603.49)	/ 2 )
	=	640.43	/	7465.9975
	=	8.58 %

KAINOS Laboratories's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Sep. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Sep. 2025 )		(Q: Mar. 2026 )
	=	420.394	/	( ( (8900.912 - 1551.301)	+	(9566.85 - 1963.36) )	/ 2 )
	=	420.394	/	( ( 7349.611	+	7603.49 )	/ 2 )
	=	420.394	/	7476.5505
	=	5.62 %

(1) Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 5.62% mean?

KAINOS Laboratories (TSE:4556) has a ROCE % of 5.62% as of Mar. 2026.

Is KAINOS Laboratories' ROCE % too high?

KAINOS Laboratories' current ROCE % is 5.62%. The Medical Devices & Instruments industry median ROCE % is 2.23. KAINOS Laboratories' value of 5.62% is 152% above this industry median. Overall, KAINOS Laboratories has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does KAINOS Laboratories' ROCE % compare to ISRG and BDX?

KAINOS Laboratories' ROCE % of 5.62% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. KAINOS Laboratories' value of 5.62% is 152% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. KAINOS Laboratories's current ROCE % of 5.62% is 152% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. KAINOS Laboratories's current ROCE % is 5.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is KAINOS Laboratories stock overvalued right now?

Based on GuruFocus' analysis, KAINOS Laboratories (TSE:4556) is currently considered Significantly Overvalued. The stock's GF Value™ is 円1,281.99, compared to a current price of 円2,268.00 — trading 76.9% above its estimated fair value. The current ROCE % is 5.62% and 152% above the Medical Devices & Instruments industry median of 2.23. KAINOS Laboratories' overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For KAINOS Laboratories (TSE:4556), the current ROCE % is 5.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is KAINOS Laboratories (TSE:4556) Overvalued in 2026?

Based on GuruFocus' analysis, KAINOS Laboratories stock appears to be overvalued. The current stock price of 円2,268.00 is trading 76.9% above its estimated GF Value™ of 円1,281.99. GuruFocus considers KAINOS Laboratories to be Significantly Overvalued.

Key valuation signals for TSE:4556:

ROCE %: 5.62%
GF Value™: 円1,281.99 vs. price of 円2,268.00 (76.9% above fair value)
GF Score™: 39/100 with 6 warning signs
Industry Position: 152% above the Medical Devices & Instruments median

No single metric tells the full story. See the TSE:4556 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

KAINOS Laboratories Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies TSE:7702 TSE:3446 TSE:7775 TSE:9340 TSE:7980 TSE:7743 TSE:7813 TSE:7782 TSE:3154 TSE:7749 ISRG XPAR:EL TSE:7741 BDX XSWX:ALC MDLN RMD WST TSE:4543 XPAR:DIM

Address 38-18, Hongo 2-chome, Bunkyo-ku, Tokyo, JPN

Website http://www.kainos.co.jp

KAINOS Laboratories Inc is focused on the development, manufacture, marketing, distribution, and import/export of pharmaceuticals, diagnostic reagents, and related chemical products. It also manufactures, sells, and exports/imports physicochemical measuring equipment for medical use.

39GF Score

Get the complete analysis for TSE:4556

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円2,268.00

Price

円1,281.99

GF Value

View TSE:4556 Analysis

See ROCE % data for all stocks →